Clinical Trials

An Extended/Phase 2, Multi-Center, Randomized, Open-Label Study to Evaluate the Safety and Tolerability of GT0918 in Subjects With Metastatic Castrate Resistant Prostate Cancer (mCRPC) Who Failed Either Abiraterone or Enzalutamide

• Condition: Metastatic Castrate Resistant Prostate Cancer (mCRPC)
• Intervention: Drug: GT0918
• Study ID: NCT03899467

Hypofractionated Radiosurgery for Localised Prostate Cancer

• Condition: Prostate Cancer
• Intervention: Radiation: Hypofractionated Radiosurgery
• Study ID: NCT03795337

A Phase 3, Randomized, Double-Blind Study of Nivolumab or Placebo in Combination With Docetaxel, in Men With Metastatic Castration-resistant Prostate Cancer

• Condition: Prostate Cancer
• Intervention: Biological: nivolumab, Drug: prednisone, Drug: docetaxel
• Study ID: NCT04100018

A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Apalutamide in Subjects With High-risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy

• Condition: Prostatic Neoplasms
• Intervention: Drug: Apalutamide, Drug: Androgen Deprivation Therapy (ADT), Drug: Placebo
• Study ID: NCT03767244

Phase 3, Multicenter, Randomized Study, Evaluating the Efficacy and Tolerability of Focused HIFU Therapy Compared to Active Surveillance in Patients With Significant Low Risk Prostate Cancer

• Condition: Prostate Cancer
• Intervention: Procedure: treatment with focal HIFU, Biological: PSA dosage, Device: MRI, Other: Questionnaires, Procedure: Prostatic biopsies
• Study ID: NCT03531099

A Phase I Trial of Fractionated Docetaxel and Radium 223 in Metastatic Castration-Resistant Prostate Cancer (CRPC)

• Condition: Metastatic Castrate Resistant Prostate Cancer
• Intervention: Drug: Docetaxel, Radiation: Radium 223
• Study ID: NCT03737370

A Phase 1/2 Study of REGN5678 (Anti-PSMAxCD28) With Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-resistant Prostate Cancer

• Condition: Metastatic Castration-resistant Prostate Cancer
• Intervention: Drug: REGN5678, Drug: Cemiplimab
• Study ID: NCT03972657

A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Re

• Condition: Metastatic Castrate Sensitive Prostate Cancer
• Study ID: NCT04497844

A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib+Abiraterone Versus Placebo+Abiraterone as Treatment for Patients With DeNovo Metastatic Hormone-Sensitive Prostate Cancer Characterised by PTE

• Condition: Hormone-Sensitive Prostate Cancer
• Study ID: NCT04493853

Prostate Cancer Biomarker Enrichment and Treatment Selection (PC-BETS) Study

• Condition: Prostate Cancer
• Intervention: Drug: AZD1775, Drug: Savolitinib, Drug: Darolutamide
• Study ID: NCT03385655

A Study to Evaluate the Safety and Efficacy of IMMU-132 (Sacituzumab Govitecan) in Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Progressed on Second Generation AR-Directed Therapy

• Condition: Prostate Cancer
• Intervention: Drug: IMMU-132
• Study ID: NCT03725761

Phase I/II Dose-escalation Study of Fractionated and Multiple Dose 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer

• Condition: Prostate Cancer
• Study ID: NCT04506567

A Phase 3, Open-Label, Randomized Study Evaluating Metastatic Castrate Resistant Prostate Cancer Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment (SPLASH)

• Condition: Metastatic Castration-Resistant Prostate Cancer
• Study ID: NCT04647526

A Randomized Phase II Study of 177 LuPSMA-617 vs Docetaxel in Patients With Metastatic Castration-Resistant Prostate Cancer and PSMA-Positive Disease

• Condition: Prostate Cancer
• Study ID: NCT04663997

PSMAfore: A Phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in the Treatment of Taxane Naïve Men With Progressive Metastatic Castrate Resistant Prostate Cancer

• Condition: Prostatic Neoplasms
• Intervention:
  Warning: array_map(): Expected parameter 2 to be an array, string given in /home/verus/public_html/components/com_clinicaltrials/views/search/tmpl/search-results.php on line 55
  
  Warning: implode(): Invalid arguments passed in /home/verus/public_html/components/com_clinicaltrials/views/search/tmpl/search-results.php on line 55
  
• Study ID: NCT04689828

Protocol for the Development of a Machine Learning Model for Prostate Cancer Treatment Planning

• Condition: Prostate Cancer, Artificial Intelligence, Radiotherapy
• Study ID: NCT04441775

Early Detection of Prostate Cancer by Liquid Biopsy

• Condition: Prostate Cancer
• Study ID: NCT04556916

A Phase 1, Open-label Study in Two Parts, Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Activity of CCW702 in Patients With Metastatic, Castration Resistant Prostate Adenocarcinoma

• Condition: Castration-Resistant Prostatic Cancer
• Intervention: Drug: CCW702
• Study ID: NCT04077021

• Condition: Prostate Cancer
• Study ID: NCT04390880

A Phase II Multi-Center Trial of Abemaciclib With or Without Atezolizumab in Metastatic Castration Resistant Prostate Cancer

• Condition: Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
• Study ID: NCT04751929

Local Cytoreductive Treatments for Men With Newly Diagnosed Metastatic Prostate Cancer in Addition to Standard of Care Treatment

• Condition: Prostate Cancer, Metastatic Prostate Cancer
• Intervention: Combination Product: Standard of Care, Procedure: Minimally Invasive Ablative Therapy (MIAT), Procedure: Radical Therapy (Prostatectomy or Radiotherapy)
• Study ID: NCT03763253

A Phase IIA Study of Sequential ("First Strike, Second Strike") Therapies, Modeled on Evolutionary Dynamics of Anthropocene Extinctions, for High Risk Metastatic Castration Sensitive Prostate Cancer

• Condition: Prostate Cancer, Stage IV Prostate Cancer
• Study ID: NCT05189457

Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*)

• Condition: Metastatic Malignant Neoplasm in the Bone, Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
• Study ID: NCT04513717

A Multi-Center, Open-Label, Randomized Phase 3 Trial Comparing the Safety and Efficacy of 177Lu-PSMA-I&T Versus Hormone Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer

• Condition: Metastasis From Malignant Tumor of Prostate
• Study ID: NCT05204927

A Multi-Center, Open-Label, Randomized Phase 2 Study of Copper Cu 64 PSMA I&T Injection in Patients With Histologically Proven Metastatic Prostate Cancer

• Condition: Metastasis From Malignant Tumor of Prostate (Disorder)
• Study ID: NCT05653856

A Phase 2, Open-label, Randomized Controlled Trial of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer

• Condition: Prostatic Neoplasms, Castration-Resistant
• Study ID: NCT05169684

Randomized Phase II Trial of Five or Two MRI-Guided Adaptive Radiotherapy Treatments for Prostate Cancer

• Condition: Prostate Cancer
• Study ID: NCT04984343

Randomized Phase II Trial of Salvage Radiotherapy for Prostate Cancer In 4 Weeks v. 2 Weeks

• Condition: Prostate Cancer
• Study ID: NCT04422132

Feasibility Study of Radiation Therapy and IRreversible Electroporation for Intermediate Risk Prostate Cancer (RTIRE)

• Condition: Prostate Cancer
• Study ID: NCT05345444

Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE)

• Condition: Prostate Adenocarcinoma
• Study ID: NCT05050084

A Phase 2 Trial of ADT Interruption in Patients Responding Exceptionally to AR-Pathway Inhibitor in Metastatic Hormone-Sensitive Prostate Cancer (MHSPC): A-DREAM

• Condition: Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
• Study ID: NCT05241860